Breast Cancer

, Volume 18, Issue 4, pp 244–251 | Cite as

Radiation therapy for brain metastases in breast cancer patients

Special Feature Strategies of radiotherapy for recurrent and metastatic breast cancer

Abstract

Most randomized comparison trials (RCTs) investigating treatments for brain metastases (BM) have included BM from any origin; as a result, more than half (52.4–77.0%) of the BM in these trials originated from the lungs (mostly non-small-cell lung cancer, NSCLC), with the breasts being the origin in only 6.8–19.0% of cases. In addition, patients with poor systemic status (KPS < 70) were not included in these trials. Hence, before we can apply RCT-based information to the daily clinical treatment of BM from breast cancers, it will be crucial to differentiate the characteristics of BM originating from NSCLC and BM originating from breast cancer. Although stereotactic radiosurgery (SRS) is widely used in Japan, level-1 evidence suggests that the benefit of using SRS in addition to whole-brain radiation therapy (WBRT) has been proven only for patients with a single BM. Treatment with SRS alone, which is widely used in Japan, seems attractive because it could avoid the risk of long-term adverse effects of WBRT. However, level-1 evidence suggests that the omission of WBRT results in a high frequency of brain tumor recurrence (BTR). In an RCT between SRS-alone and SRS + WBRT conducted in Japan, we found that patients who had a single BM and no extracranial metastases had a low risk of developing BTR after initial brain management (low-risk group) compared with those who had 2 or more BM and extracranial metastases (high-risk group). In order to meet the criteria of “low-risk” BTR, patients also should have good systemic status (KPS ≧ 70). Epidemiologic data suggest that the prognosis is twice as likely to be poor in patients with BM from breast cancer (RPA III = KPS < 70) than in patients with BM from NSCLC (40 vs. 20%); in addition, the probability of brain-only metastases in patients with breast cancer is less than half that in patients with NSCLC (20–25 vs. 60–75%). Considering these findings, we should be aware that most patients with BM from breast cancer are not good candidates for SRS alone, and, therefore, the role of WBRT is still important in the era of modern radiation techniques.

Keywords

Breast cancer Brain metastases Radiation therapy Stereotactic radiosurgery Whole-brain radiation therapy 

Notes

Conflict of interest statement

None.

References

  1. 1.
    Tsukada Y, Fouad A, Pickren JW, Lane WW. Central nervous system metastasis from breast carcinoma. Autopsy Study Cancer. 1983;52(12):2349–54.Google Scholar
  2. 2.
    Nussbaum ES, Djalilian HR, Cho KH, Hall WA. Brain metastases. Histology, multiplicity, surgery, and survival. Cancer. 1996;78(8):1781–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Frazier JL, Batra S, Kapor S, Vellimana A, Gandhi R, Carson KA, et al. Stereotactic radiosurgery in the management of brain metastases: an institutional retrospective analysis of survival. Int J Radiat Oncol Biol Phys. 2010;76(5):1486–92.PubMedCrossRefGoogle Scholar
  4. 4.
    Golden DW, Lamborn KR, McDermott MW, Kunwar S, Wara WM, Nakamura JL, et al. Prognostic factors and grading systems for overall survival in patients treated with radiosurgery for brain metastases: variation by primary site. J Neurosurg. 2008;109:77–86.PubMedCrossRefGoogle Scholar
  5. 5.
    Lorenzoni J, Devriendt D, Massager N, David P, Ruiz S, Vanderlinden B, et al. Radiosurgery for treatment of brain metastases: estimation of patient eligibility using three stratification systems. Int J Radiat Oncol Biol Phys. 2004;60(1):218–24.PubMedCrossRefGoogle Scholar
  6. 6.
    Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322(8):494–500.PubMedCrossRefGoogle Scholar
  7. 7.
    Vecht CJ, Haaxma-Reiche H, Noordijk EM, Padberg GW, Voormolen JH, Hoekstra FH, et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol. 1993;33(6):583–90.PubMedCrossRefGoogle Scholar
  8. 8.
    Mintz AH, Kestle J, Rathbone MP, Gaspar L, Hugenholtz H, Fisher B, et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer. 1996;78(7):1470–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA. 1998;280(17):1485–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006;295(21):2483–91.PubMedCrossRefGoogle Scholar
  11. 11.
    Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363(9422):1665–72.PubMedCrossRefGoogle Scholar
  12. 12.
    Boogerd W, Vos VW, Hart AA, Baris G. Brain metastases in breast cancer; natural history, prognostic factors and outcome. J Neurooncol. 1993;15(2):165–74.PubMedCrossRefGoogle Scholar
  13. 13.
    DiStefano A, Yong Yap Y, Hortobagyi GN, Blumenschein GR. The natural history of breast cancer patients with brain metastases. Cancer. 1979;44(5):1913–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Mehta MP, Rodrigus P, Terhaard CH, Rao A, Suh J, Roa W, et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol. 2003;21(13):2529–36.PubMedCrossRefGoogle Scholar
  15. 15.
    Schouten LJ, Rutten J, Huveneers HA, Twijnstra A. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer. 2002;94(10):2698–705.PubMedCrossRefGoogle Scholar
  16. 16.
    Gaspar LE, Chansky K, Albain KS, Vallieres E, Rusch V, Crowley JJ, et al. Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: a retrospective review by the Southwest Oncology Group. J Clin Oncol. 2005;23(13):2955–61.PubMedCrossRefGoogle Scholar
  17. 17.
    Ono M, Ando M, Yunokawa M, Nakano E, Yonemori K, Matsumoto K, et al. Brain metastases in patients who receive trastuzumab-containing chemotherapy for HER2-overexpressing metastatic breast cancer. Int J Clin Oncol. 2009;14(1):48–52.PubMedCrossRefGoogle Scholar
  18. 18.
    Maki DD, Grossman RI. Patterns of disease spread in metastatic breast carcinoma: influence of estrogen and progesterone receptor status. AJNR Am J Neuroradiol. 2000;21(6):1064–6.PubMedGoogle Scholar
  19. 19.
    Gabos Z, Sinha R, Hanson J, Chauhan N, Hugh J, Mackey JR, et al. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol. 2006;24(36):5658–63.PubMedCrossRefGoogle Scholar
  20. 20.
    Atahan IL, Ozyigit G, Yildiz F, Gurkaynak M, Selek U, Sari S, et al. Percent positive axillary involvement predicts for the development of brain metastasis in high-risk patients with nonmetastatic breast cancer receiving post-mastectomy radiotherapy. Breast J. 2008;14(3):245–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Saip P, Cicin I, Eralp Y, Karagol H, Kucucuk S, Cosar Alas R, et al. Identification of patients who may benefit from the prophylactic cranial radiotherapy among breast cancer patients with brain metastasis. J Neurooncol. 2009;93(2):243–51.PubMedCrossRefGoogle Scholar
  22. 22.
    Duchnowska R, Dziadziuszko R, Czartoryska-Arlukowicz B, Radecka B, Szostakiewicz B, Sosinska-Mielcarek K, et al. Risk factors for brain relapse in HER2-positive metastatic breast cancer patients. Breast Cancer Res Treat. 2009;117(2):297–303.PubMedCrossRefGoogle Scholar
  23. 23.
    Lee SS, Ahn JH, Kim MK, Sym SJ, Gong G, Ahn SD, et al. Brain metastases in breast cancer prognostic factors and management. Breast Cancer Res Treat. 2008;111(3):523–30.PubMedCrossRefGoogle Scholar
  24. 24.
    Leyland-Jones B. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J Clin Oncol. 2009;27(31):5278–86.PubMedCrossRefGoogle Scholar
  25. 25.
    Miller KD, Weathers T, Haney LG, Timmerman R, Dickler M, Shen J, et al. Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. Ann Oncol. 2003;14(7):1072–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Matsumoto K, Ando M, Yamauchi C, Egawa C, Hamamoto Y, Kataoka M, et al. Questionnaire survey of treatment choice for breast cancer patients with brain metastasis in Japan: results of a nationwide survey by the task force of the Japanese Breast Cancer Society. Jpn J Clin Oncol. 2009;39(1):22–6.PubMedCrossRefGoogle Scholar
  27. 27.
    Lai R, Dang CT, Malkin MG, Abrey LE. The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer. 2004;101(4):810–6.PubMedCrossRefGoogle Scholar
  28. 28.
    Wolstenholme V, Hawkins M, Ashley S, Tait D, Ross G. HER2 significance and treatment outcomes after radiotherapy for brain metastases in breast cancer patients. Breast. 2008;17(6):661–5.PubMedCrossRefGoogle Scholar
  29. 29.
    Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer. 2007;7:153.PubMedCrossRefGoogle Scholar
  30. 30.
    Lower EE, Drosick DR, Blau R, Brennan L, Danneman W, Hawley DK. Increased rate of brain metastasis with trastuzumab therapy not associated with impaired survival. Clin Breast Cancer. 2003;4(2):114–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Niwinska A, Murawska M, Pogoda K. Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Ann Oncol. Oct 19 2009.Google Scholar
  32. 32.
    Liu MT, Hsieh CY, Wang AY, Chang TH, Pi CP, Huang CC, et al. Prognostic factors affecting the outcome of brain metastases from breast cancer. Support Care Cancer. 2006;14(9):936–42.PubMedCrossRefGoogle Scholar
  33. 33.
    Viani GA, Castilho MS, Salvajoli JV, Pellizzon AC, Novaes PE, Guimaraes FS, et al. Whole brain radiotherapy for brain metastases from breast cancer estimation of survival using two stratification systems. BMC Cancer. 2007;7:53.PubMedCrossRefGoogle Scholar
  34. 34.
    Goyal S, Prasad D, Harrell F Jr, Matsumoto J, Rich T, Steiner L. Gamma knife surgery for the treatment of intracranial metastases from breast cancer. J Neurosurg. 2005;103(2):218–23.PubMedCrossRefGoogle Scholar
  35. 35.
    Socinski MA, Langer CJ, Huang JE, Matsumoto J, Rich T, Steiner L. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol. 2009;27(31):5255–61.PubMedCrossRefGoogle Scholar
  36. 36.
    Seute T, Leffers P, ten Velde GP, Twijnstra A. Detection of brain metastases from small cell lung cancer: consequences of changing imaging techniques (CT versus MRI). Cancer. 2008;112(8):1827–34.PubMedCrossRefGoogle Scholar
  37. 37.
    Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37(4):745–51.PubMedCrossRefGoogle Scholar
  38. 38.
    Agboola O, Benoit B, Cross P, Da Silva V, Esche B, Lesiuk H, et al. Prognostic factors derived from recursive partition analysis (RPA) of Radiation Therapy Oncology Group (RTOG) brain metastases trials applied to surgically resected and irradiated brain metastatic cases. Int J Radiat Oncol Biol Phys. 1998;42(1):155–9.PubMedGoogle Scholar
  39. 39.
    Chidel MA, Suh JH, Reddy CA, Chao ST, Lundbeck MF, Barnett GH. Application of recursive partitioning analysis and evaluation of the use of whole brain radiation among patients treated with stereotactic radiosurgery for newly diagnosed brain metastases. Int J Radiat Oncol Biol Phys. 2000;47(4):993–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Sanghavi SN, Miranpuri SS, Chappell R, Buatti JM, Sneed PK, Suh JH, et al. Radiosurgery for patients with brain metastases: a multi-institutional analysis, stratified by the RTOG recursive partitioning analysis method. Int J Radiat Oncol Biol Phys. 2001;51(2):426–34.PubMedCrossRefGoogle Scholar
  41. 41.
    Samuel TC, Gene HB, Stephanie WL, Alwyn MR, Steven AT, Michael AV, et al. Five-year survivors of brain metastases: a single-institution report of 32 patients. Int J Radiat Oncol Biol Phys. 2006;66(3):801–9.CrossRefGoogle Scholar
  42. 42.
    Gregory MMV, Chandana AR, Samuel TC, Thomas WR, David JA, Gene HB, et al. Gender, race, and survival: a study in non-small-cell lung cancer brain metastases patients utilizing the Radiation Therapy Oncology Group recursive partitioning analysis classification. Int J Radiat Oncol Biol Phys. 2009;75(4):1141–7.CrossRefGoogle Scholar
  43. 43.
    Akyurek S, Chang EL, Mahajan A, Hassenbusch SJ, Allen PK, Mathews LA, et al. Stereotactic radiosurgical treatment of cerebral metastases arising from breast cancer. Am J Clin Oncol. 2007;30(3):310–4.PubMedCrossRefGoogle Scholar
  44. 44.
    Rades D, Lohynska R, Veninga T, Stalpers LJ, Schild SE. Evaluation of 2 whole-brain radiotherapy schedules and prognostic factors for brain metastases in breast cancer patients. Cancer. 2007;110(11):2587–92.PubMedCrossRefGoogle Scholar
  45. 45.
    Le Scodan R, Massard C, Mouret-Fourme E, Guinebretierre JM, Cohen-Solal C, De Lalande B, et al. Brain metastases from breast carcinoma: validation of the Radiation Therapy Oncology Group recursive partitioning analysis classification and proposition of a new prognostic score. Int J Radiat Oncol Biol Phys. 2007;69(3):839–45.PubMedCrossRefGoogle Scholar
  46. 46.
    Harputluoglu H, Dizdar O, Aksoy S, Kilickap S, Dede DS, Ozisik Y, et al. Characteristics of breast cancer patients with central nervous system metastases: a single-center experience. J Natl Med Assoc. 2008;100(5):521–6.PubMedGoogle Scholar
  47. 47.
    Boogerd W, Hart AA, Tjahja IS. Treatment and outcome of brain metastasis as first site of distant metastasis from breast cancer. J Neurooncol. 1997;35(2):161–7.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Breast Cancer Society 2010

Authors and Affiliations

  1. 1.Division of Radiation Oncology, Department of RadiologyNiigata University Graduate School of Medical and Dental SciencesNiigataJapan

Personalised recommendations